◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Sun Pharmaceutical Industries Limited (SUNPHARMA) Revenue 2023–2026

Name: Sun Pharmaceutical Industries Limited (SUNPHARMA) revenue history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Sun Pharmaceutical Industries Limited annual revenue for fiscal 2026 was ₹582.2 billion, an increase of 11.9% from ₹520.4 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

SUNPHARMA Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹582.2B	₹520.4B	₹477.6B	₹432.8B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SUNPHARMA Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Total Revenue	₹151.8B	₹145.6B	₹154.7B	₹137.9B	₹128.2B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

4502 Revenue — Takeda Pharmaceutical Company Limited
4507 Revenue — Shionogi & Co., Ltd.
DIVISLAB Revenue — Divi's Laboratories Limited
TORNTPHARM Revenue — Torrent Pharmaceuticals Limited
4523 Revenue — Eisai Co., Ltd.
4151 Revenue — Kyowa Kirin Co., Ltd.

More SUNPHARMA metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All SUNPHARMA financial statements → Interactive SUNPHARMA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.